US EditionMainz Biomed announces financial results for 2024 and provides information on corporate development - Mainz Biomed
Summary by Mainz Biomed
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Revenue from sales through its laboratory partner network increased by 33% year-on-year, reflecting strong demand for ColoAlert® in Europe Operating loss decreased by 30% and net loss by 18%, the result of targeted cost-cutting measures and a stronger strategic focus Strategic partnerships with industry-leading companies mark significant progress The company reports on its first achievements in fiscal year 2025 BERKELEY, USA and MAINZ, Germany –…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
